OncLive | Ofatumumab Improves Response Rates, PFS in Elderly/Unfit Patients With CLL OncLive In older CLL patients who are unfit for the gold-standard therapy of fludarabine-cyclophosphamide-rituximab, chlorambucil using a variety of dosing schedules remains a treatment option, said Hillmen, consultant hematologist, Leeds Teaching Hospitals ... |
